Literature DB >> 22369580

Hydrodynamic and functional analysis of HIV-1 Vif oligomerization.

Stephen M Techtmann1, Rodolfo Ghirlando, Sandra Kao, Klaus Strebel, Ernest L Maynard.   

Abstract

HIV-1 Vif is an accessory protein that induces the proteasomal degradation of the host restriction factor, apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G (APOBEC3G). The N-terminal half of Vif binds to APOBEC3G, and the C-terminal half binds to subunits of a cullin 5-based ubiquitin ligase. This Vif-directed ubiquitin ligase induces the degradation of APOBEC3G (a cytidine deaminase) and thereby protects the viral genome from mutation. A conserved PPLP motif near the C-terminus of Vif is essential for Vif function and is also involved in Vif oligomerization. However, the mechanism and functional significance of Vif oligomerization is unclear. We employed analytical ultracentrifugation to examine the oligomeric properties of Vif in solution. Contrary to previous reports, we find that Vif oligomerization does not require the conserved PPLP motif. Instead, our data suggest a more complex mechanism involving interactions among the HCCH motif, the BC box, and downstream residues in Vif. Mutation of residues near the PPLP motif (S165 and V166) affected the oligomeric properties of Vif and weakened the ability of Vif to bind and induce the degradation of APOBEC3G. We propose that Vif oligomerization may represent a mechanism for regulating interactions with APOBEC3G.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22369580      PMCID: PMC3302947          DOI: 10.1021/bi201738a

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  69 in total

1.  Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex.

Authors:  Xianghui Yu; Yunkai Yu; Bindong Liu; Kun Luo; Wei Kong; Panyong Mao; Xiao-Fang Yu
Journal:  Science       Date:  2003-10-16       Impact factor: 47.728

2.  Hypermutation of HIV-1 DNA in the absence of the Vif protein.

Authors:  Denise Lecossier; Francine Bouchonnet; François Clavel; Allan J Hance
Journal:  Science       Date:  2003-05-16       Impact factor: 47.728

3.  DNA deamination mediates innate immunity to retroviral infection.

Authors:  Reuben S Harris; Kate N Bishop; Ann M Sheehy; Heather M Craig; Svend K Petersen-Mahrt; Ian N Watt; Michael S Neuberger; Michael H Malim
Journal:  Cell       Date:  2003-06-13       Impact factor: 41.582

4.  Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.

Authors:  Bin Yang; Ling Gao; Lin Li; Zhixian Lu; Xuejun Fan; Charvi A Patel; Roger J Pomerantz; Garrett C DuBois; Hui Zhang
Journal:  J Biol Chem       Date:  2002-12-11       Impact factor: 5.157

5.  Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein.

Authors:  Ann M Sheehy; Nathan C Gaddis; Jonathan D Choi; Michael H Malim
Journal:  Nature       Date:  2002-07-14       Impact factor: 49.962

6.  Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif.

Authors:  Roberto Mariani; Darlene Chen; Bärbel Schröfelbauer; Francisco Navarro; Renate König; Brooke Bollman; Carsten Münk; Henrietta Nymark-McMahon; Nathaniel R Landau
Journal:  Cell       Date:  2003-07-11       Impact factor: 41.582

7.  The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA.

Authors:  Hui Zhang; Bin Yang; Roger J Pomerantz; Chune Zhang; Shyamala C Arunachalam; Ling Gao
Journal:  Nature       Date:  2003-05-28       Impact factor: 49.962

8.  Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.

Authors:  Bastien Mangeat; Priscilla Turelli; Gersende Caron; Marc Friedli; Luc Perrin; Didier Trono
Journal:  Nature       Date:  2003-05-28       Impact factor: 49.962

9.  HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation.

Authors:  Mariana Marin; Kristine M Rose; Susan L Kozak; David Kabat
Journal:  Nat Med       Date:  2003-10-05       Impact factor: 53.440

10.  HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability.

Authors:  Kim Stopak; Carlos de Noronha; Wes Yonemoto; Warner C Greene
Journal:  Mol Cell       Date:  2003-09       Impact factor: 17.970

View more
  6 in total

Review 1.  Structural insights for HIV-1 therapeutic strategies targeting Vif.

Authors:  Jason D Salter; Guillermo A Morales; Harold C Smith
Journal:  Trends Biochem Sci       Date:  2014-08-12       Impact factor: 13.807

2.  Characterization of RNA binding and chaperoning activities of HIV-1 Vif protein. Importance of the C-terminal unstructured tail.

Authors:  Dona Sleiman; Serena Bernacchi; Santiago Xavier Guerrero; Franck Brachet; Valéry Larue; Jean-Christophe Paillart; Carine Tisne
Journal:  RNA Biol       Date:  2014-07-22       Impact factor: 4.652

3.  CBFβ stabilizes HIV Vif to counteract APOBEC3 at the expense of RUNX1 target gene expression.

Authors:  Dong Young Kim; Eunju Kwon; Paul D Hartley; David C Crosby; Sumanjit Mann; Nevan J Krogan; John D Gross
Journal:  Mol Cell       Date:  2013-01-17       Impact factor: 17.970

4.  APOBEC3G impairs the multimerization of the HIV-1 Vif protein in living cells.

Authors:  Julien Batisse; Santiago Xavier Guerrero; Serena Bernacchi; Ludovic Richert; Julien Godet; Valérie Goldschmidt; Yves Mély; Roland Marquet; Hugues de Rocquigny; Jean-Christophe Paillart
Journal:  J Virol       Date:  2013-04-10       Impact factor: 5.103

5.  The HIVToolbox 2 web system integrates sequence, structure, function and mutation analysis.

Authors:  David P Sargeant; Sandeep Deverasetty; Christy L Strong; Izua J Alaniz; Alexandria Bartlett; Nicholas R Brandon; Steven B Brooks; Frederick A Brown; Flaviona Bufi; Monika Chakarova; Roxanne P David; Karlyn M Dobritch; Horacio P Guerra; Michael W Hedden; Rma Kumra; Kelvy S Levitt; Kiran R Mathew; Ray Matti; Dorothea Q Maza; Sabyasachy Mistry; Nemanja Novakovic; Austin Pomerantz; Josue Portillo; Timothy F Rafalski; Viraj R Rathnayake; Noura Rezapour; Sarah Songao; Sean L Tuggle; Sandy Yousif; David I Dorsky; Martin R Schiller
Journal:  PLoS One       Date:  2014-06-02       Impact factor: 3.240

6.  Insight into the HIV-1 Vif SOCS-box-ElonginBC interaction.

Authors:  Zhisheng Lu; Julien R C Bergeron; R Andrew Atkinson; Torsten Schaller; Dennis A Veselkov; Alain Oregioni; Yi Yang; Stephen J Matthews; Michael H Malim; Mark R Sanderson
Journal:  Open Biol       Date:  2013-11-13       Impact factor: 6.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.